Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Fulvestrant 4trastuzumab deruxtecan 2elacestrant 2Vinorelbine 2AZD9833 2toripalimab 1talazoparib 1ribociclib 1pyrotinib 1palbociclib 1olaparib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1Radiotherapy 1RAD1901 1Letrozole 1Injections 1Gonadotropin-Releasing Hormone 1Everolimus 1Capecitabine 1Aromatase Inhibitors 1Anastrozole 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Breast Cancer × apatinib × Clear all
NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Fudan University

Phase 3 Recruiting
184 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡